1. Biotech Entrepreneur, CEO: Over 20 years in biotech/ biopharma industry starting, leading & growing successful organizations. Received Johnson & Johnson Entrepreneur Innovator award (inaugural recipient). Founder/ co-Founder & CEO of four biotherapeutics companies. 2. Clinician-Scientist, Experimental Therapeutics: Leader in novel biotherapeutic classes including gene therapy, viral vectors and targeted oncolytic & immunotherapeutic viruses for cancer (Phase 2b; Nature Rev Cancer 2009). Harvard and UC San Francisco trained clinician-scientist. Faculty positions (full-time or adjunct): UC Berkeley, Bioengineering (current), UC San Francisco, University of Oxford, Imperial College London. Over 100 publications including senior author in the following journals: Nature, Nature Medicine (n=7), Nature Reviews Cancer, Nature Biotech, Nature Reviews Clinical Oncology, Science Translational Med, Lancet Oncol (n=2), JCI (n=3), PLoS Medicine, JCO, Cancer Res (n=9). 3. Cancer Therapeutics R&D, Clinical Development: Has led development of multiple, diverse product classes from translational to late-stage clinical R&D: complex biologics (immunotherapy, oncolytic viruses, gene therapy), monoclonal antibodies, cytokines, small molecule kinase inhibitors, including first sorafenib (Nexavar) development plan Onyx-Bayer; first approved targeted product for liver, renal cancers. Experienced in discovery, preclinical pharm/tox, IND, Phase 1-3.